280 related articles for article (PubMed ID: 23764080)
1. Multiplex protein signature for the detection of bladder cancer in voided urine samples.
Rosser CJ; Ross S; Chang M; Dai Y; Mengual L; Zhang G; Kim J; Urquidi V; Alcaraz A; Goodison S
J Urol; 2013 Dec; 190(6):2257-62. PubMed ID: 23764080
[TBL] [Abstract][Full Text] [Related]
2. A multi-analyte assay for the non-invasive detection of bladder cancer.
Goodison S; Chang M; Dai Y; Urquidi V; Rosser CJ
PLoS One; 2012; 7(10):e47469. PubMed ID: 23094052
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection.
Urquidi V; Goodison S; Kim J; Chang M; Dai Y; Rosser CJ
Urology; 2012 May; 79(5):1185.e1-6. PubMed ID: 22386755
[TBL] [Abstract][Full Text] [Related]
4. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
5. Urinary protein biomarker panel for the detection of recurrent bladder cancer.
Rosser CJ; Chang M; Dai Y; Ross S; Mengual L; Alcaraz A; Goodison S
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1340-5. PubMed ID: 24714076
[TBL] [Abstract][Full Text] [Related]
6. CCL18 in a multiplex urine-based assay for the detection of bladder cancer.
Urquidi V; Kim J; Chang M; Dai Y; Rosser CJ; Goodison S
PLoS One; 2012; 7(5):e37797. PubMed ID: 22629457
[TBL] [Abstract][Full Text] [Related]
7. IL-8 as a urinary biomarker for the detection of bladder cancer.
Urquidi V; Chang M; Dai Y; Kim J; Wolfson ED; Goodison S; Rosser CJ
BMC Urol; 2012 May; 12():12. PubMed ID: 22559832
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms.
Furuya H; Sakatani T; Tanaka S; Murakami K; Waldron RT; Hogrefe W; Rosser CJ
J Transl Med; 2024 Jan; 22(1):8. PubMed ID: 38167321
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology.
Eissa S; Salem AM; Zohny SF; Hegazy MG
Cancer Biomark; 2007; 3(6):275-85. PubMed ID: 18048965
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of urinary molecular markers in bladder cancer.
Eissa S; Swellam M; el-Mosallamy H; Mourad MS; Hamdy NΜ; Kamel K; Zaglol AS; Khafagy MM; el-Ahmady O
Anticancer Res; 2003; 23(5b):4347-55. PubMed ID: 14666650
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer.
Urquidi V; Goodison S; Ross S; Chang M; Dai Y; Rosser CJ
J Urol; 2012 Dec; 188(6):2377-83. PubMed ID: 23088986
[TBL] [Abstract][Full Text] [Related]
13. A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort.
Goodison S; Ogawa O; Matsui Y; Kobayashi T; Miyake M; Ohnishi S; Fujimoto K; Dai Y; Shimizu Y; Tsukikawa K; Furuya H; Rosser CJ
J Transl Med; 2016 Oct; 14(1):287. PubMed ID: 27717367
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of Oncuria™, a urinalysis test for bladder cancer.
Hirasawa Y; Pagano I; Chen R; Sun Y; Dai Y; Gupta A; Tikhonenkov S; Goodison S; Rosser CJ; Furuya H
J Transl Med; 2021 Apr; 19(1):141. PubMed ID: 33823873
[TBL] [Abstract][Full Text] [Related]
15. The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors.
Smrkolj T; Cegovnik Primozic U; Fabjan T; Sterpin S; Osredkar J
Radiol Oncol; 2020 Dec; 55(2):196-202. PubMed ID: 33764701
[TBL] [Abstract][Full Text] [Related]
16. A multiplex immunoassay for the non-invasive detection of bladder cancer.
Shimizu Y; Furuya H; Bryant Greenwood P; Chan O; Dai Y; Thornquist MD; Goodison S; Rosser CJ
J Transl Med; 2016 Jan; 14():31. PubMed ID: 26830497
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer.
Shabayek MI; Sayed OM; Attaia HA; Awida HA; Abozeed H
Pathol Oncol Res; 2014 Oct; 20(4):859-66. PubMed ID: 24696417
[TBL] [Abstract][Full Text] [Related]
18. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
